Wuxi Biologics Placement - Similar Deal Will Yield Similar Results
Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 1.8% of Wuxi Biologics (2269 HK). This is the company's 15th placement...
365 Views
HCM Secondary Trading: NPMA Approvals Warrant a Pop on Debut
We look updates from HCM since it launched its book building. We note that the recent NMPA approval will result in a share price pop on debut.
209 Views
China Healthcare Weekly (Jun.25)
This article analyzed the results of 5th national volume-based purchase, the new announcement on the centralized procurement of artificial joints,...
226 Views
Pre-IPO Hutchmed China Ltd (13.HK) - The Strength and the Concerns
The article analyzed Hutchmed in terms of its business analysis, financial performance, pipeline, comparison with other biotech companies, and also...
267 Views
HutchMed Secondary Listing: HK-ADS Premium/(Discount) Views
HutchMed has launched a $603 million secondary listing on HKEx. In this note, we will look at HutchMed’s potential HK-ADS premium/(discount).
320 Views